Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting
01 sept. 2021 08h30 HE
|
Entera Bio Ltd.
‒ Second of Two Presentations to be Delivered by Entera ‒ ‒ Final 6-Month Bone Mineral Density (BMD) Results Show Dose-Related Efficacy ‒ BOSTON and JERUSALEM, Sept. 01, 2021 (GLOBE...
Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021
23 août 2021 11h00 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its...
Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference
23 août 2021 08h30 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company’s CEO...
Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates
16 août 2021 06h30 HE
|
Entera Bio Ltd.
‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met ‒ ‒ Preparing for End of Phase 2 Meeting with FDA for...
Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021
13 août 2021 16h30 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business...
Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting
02 août 2021 08h30 HE
|
Entera Bio Ltd.
‒ The Study’s Primary Endpoint was Met; P1NP, a Biochemical Marker of Bone Formation, was Significantly Increased at Month 3 in EB613 2.5 mg Treatment Group Versus Placebo ‒ ‒ Full 3-Month...
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis
28 juin 2021 15h15 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, June 28, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a...
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
23 juin 2021 08h30 HE
|
Entera Bio Ltd.
Subjects receiving the 2.5 mg dose of EB613 showed significant dose-related increases in BMD at the lumbar spine, total hip, and femoral neck at 6 monthsSubjects receiving the 2.5 mg dose of EB613 for...
Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union
17 juin 2021 08h00 HE
|
Entera Bio Ltd.
‒ Oral delivery technology has potential to transform $20 billion injectable biologics market ‒ ‒ Final BMD results from company’s Phase 2 Osteoporosis study of EB 613 expected in Q2/2021 ‒ ...
Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates
20 mai 2021 08h00 HE
|
Entera Bio Ltd.
‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3-Month Primary Endpoint; Final Data Including BMD Expected Q2:21 ‒ ‒ Entera’s Oral Delivery Platform Shows Potential in Indications Including...